Scientific article focuses on improving sample quality following storage

April 05, 2016 (PRLEAP.COM) Business News
Joint white paper effort by CPSI and Eppendorf highlights the impact of handling and storage on sample quality following cryopreservation

OWEGO, NY - April 5, 2016 - CPSI Biotech announced today the recent publication of a scientific white paper discussing the impact of handling processes on sample quality following cryopreservation. The white paper titled, "Biopreservation: The impact of freezing and cold storage on sample quality" (Eppendorf, White Paper No. 031) was written by Dr. John M. Baust (President and Lead Scientist, CPSI Biotech) at the request of Eppendorf's technical team in response to growing requests by clients for more information related to the impact of storage temperature and the handling of samples prior to, during and following preservation.

In regards to the publication, Dr. Uschkureit (Eppendorf AG/ Germany) stated "Out in the field in front of our customers our team is often asked how to improve sample freezing and what the rationale is behind todays protocols. Through continued discussions with clients we realized the need for an accessible white paper and reached out to Dr. Baust, a recognized expert in the field, about collaborating on this project." Dr. Baust continued "I was very pleased to work with Eppendorf on this project. As an active researcher in the area of cryopreservation, I have experienced the impact that small changes or deviations in processing and storage protocols can have on sample quality upon retrieval. As cryopreservation is widely utilized serving as an enabling tool for many research and clinical areas, it is important for end users whom are utilizing these processes to recognize the long term impacts of various practices, so they can improve their process which will ultimately increase sample utility." Dr Baust continued "While there are a number of original research and review articles on the subject, the opportunity to partner with Eppendorf to publish this article provided a platform to reach a broader scientific audience whom could benefit from this information. The white paper style allowed us to address a number of technical components of the process (both new and established) in a semi-technical format thereby exposing readers to several critical and thought provoking areas without the often overwhelming technical jargon and data."

The article discusses the current state of cryopreservation and the impact of handling, storage and thawing protocols/conditions on sample stability and quality following retrieval. When asked about the importance of the article for Eppendorf clients, Dr. Bebermeier (Eppendorf AG/ Germany) responded "Selling and delivering a reliable product is one part, supporting the users by providing helpful material for their daily lab work is the other part of a long-term partnership. Especially topics that users are not trained on, like freezing, should be addressed by documents like this white paper." "What researchers often do not realize is that the sample is not simply a passive passenger during the preservation process, but in fact there is a complicated physical and molecular response of samples to the process. Most anyone experienced in cell culture will tell you 'cells remember how you treat them,' the same is true when preserving them" added Dr. Baust.

The article, along with numerous other technical reports and white papers published by Eppendorf, is available for free download on Eppendorf's website in the literature downloads section ( as well as from CPSI's website.

About CPSI Biotech -
CPSI Biotech, a private, integrative bio/medtech greenhouse company, develops and designs life science research products and cryo-medical devices for applications in cancer, cardiovascular disease treatments and cell therapy bioprocessing. Ongoing R&D and business development activities continue to produce innovative technologies, devices and intellectual property for commercialization, licensing or sales in support of diverse clinical and research applications. By leveraging the innovation, flexibility and R&D strengths of CPSI in combination with the development, commercialization, manufacturing and clinical expertise of partnering organizations, rapid and efficient product development is attainable.

About Eppendorf -
Eppendorf is a leading life science company that develops and sells instruments, consumables, and services for liquid handling, sample handling, and cell handling in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers, and DNA amplification equipment as well as ultra-low temperature freezers, fermenters, bioreactors, CO2 incubators, shakers and cell manipulation systems. Consumables such as pipette tips, test tubes, microliter plates, and single-use bioreactor vessels complement the range of highest-quality premium products.
Eppendorf products are most broadly used in academic and commercial research laboratories, e.g., in companies from the pharmaceutical and biotechnological as well as the chemical and food industries. They are also aimed at environmental analysis laboratories, forensics, and at industrial laboratories performing process analysis, production, and quality assurance.
Eppendorf was founded in Hamburg, Germany in 1945 and has about 2,930 employees worldwide. The company has subsidiaries in 25 countries and is represented in all other markets by distributors.

Disclosure Notice: The information contained in this release is as of April 4, 2016. CPSI assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. CPSI's technologies do not have regulatory clearance for commercial sale and are currently intended for "Research Use Only".

With the exception of the historical information contained in this release, this release contains materials and statements related to future business, financial performance, future events and/or developments involving CPSI which constitute forward-looking statements. The matters described herein contain forward-looking statements that involve risk and uncertainties that may individually or mutually impact the matters herein described, including but not limited to, CPSI's ability to develop and market new products, to retain and attract key employees, to obtain regulatory clearances and approvals for its products, to effectively react to other risks and uncertainties, such as fluctuation of quarterly financial results, contract and grants acquisition, reliance on third party manufacturers and suppliers, litigation or other proceedings, economic, competitive, governmental impacts, whether pending patents will be granted or defendable, validity of intellectual property and patents, the ability to license patents, the ability to commercialize developmental products, competition from existing and new products and procedures and CPSI's ability to raise the capital that is required to accomplish the foregoing.


CPSI Biotech Contact:
John M Baust, Ph.D., President
Kristi Snyder, Ph.D., Director of Operations

Eppendorf AG Contact:
Jan Bebermeier, Ph.D., Product Manager

Share Article